152 related articles for article (PubMed ID: 35583405)
81. [Immunophenotypes and prognosis of diffuse large B-cell lymphoma: a study of 500 cases].
Luo DL; Liu YH; Zhuang HG; Li L; Xu FP; Zhang F; Luo XL; Xu J
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):235-9. PubMed ID: 21615996
[TBL] [Abstract][Full Text] [Related]
82. Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma.
Pham-Ledard A; Prochazkova-Carlotti M; Andrique L; Cappellen D; Vergier B; Martinez F; Grange F; Petrella T; Beylot-Barry M; Merlio JP
Mod Pathol; 2014 Mar; 27(3):402-11. PubMed ID: 24030746
[TBL] [Abstract][Full Text] [Related]
83. Diagnostic value of STMN1, LMO2, HGAL, AID expression and 1p36 chromosomal abnormalities in primary cutaneous B cell lymphomas.
Verdanet E; Dereure O; René C; Tempier A; Benammar-Hafidi A; Gallo M; Frouin E; Durand L; Gazagne I; Costes-Martineau V; Cacheux V; Szablewski V
Histopathology; 2017 Oct; 71(4):648-660. PubMed ID: 28594133
[TBL] [Abstract][Full Text] [Related]
84. Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma.
El Hussein S; Medeiros LJ; Lyapichev KA; Fang H; Jelloul FZ; Fiskus W; Chen J; Wei P; Schlette E; Xu J; Li S; Kanagal-Shamanna R; Yang H; Tang Z; Thakral B; Loghavi S; Jain N; Thompson PA; Ferrajoli A; Wierda WG; Jabbour E; Patel KP; Dabaja BS; Bhalla KN; Khoury JD
Pathology; 2023 Jun; 55(4):514-524. PubMed ID: 36933995
[TBL] [Abstract][Full Text] [Related]
85. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
[TBL] [Abstract][Full Text] [Related]
86. Marginal zone B-cell lymphoma: a retrospective immunophenotypic analysis.
Kost CB; Holden JT; Mann KP
Cytometry B Clin Cytom; 2008 Sep; 74(5):282-6. PubMed ID: 18500740
[TBL] [Abstract][Full Text] [Related]
87. Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas.
Menguy S; Frison E; Prochazkova-Carlotti M; Dalle S; Dereure O; Boulinguez S; Dalac S; Machet L; Ram-Wolff C; Verneuil L; Gros A; Vergier B; Beylot-Barry M; Merlio JP; Pham-Ledard A
Mod Pathol; 2018 Aug; 31(8):1332-1342. PubMed ID: 29581544
[TBL] [Abstract][Full Text] [Related]
88. Immunohistochemical analysis of the novel marginal zone B-cell marker IRTA1 in malignant lymphoma.
Ikeda JI; Kohara M; Tsuruta Y; Nojima S; Tahara S; Ohshima K; Kurashige M; Wada N; Morii E
Hum Pathol; 2017 Jan; 59():70-79. PubMed ID: 27666766
[TBL] [Abstract][Full Text] [Related]
89. CD5-positive marginal zone lymphoma: Clinicopathological features and survival outcomes.
Xia Y; Ge J; Sun Z; Nan F; Wan W; Xu D; Zhang M; Fu X
Leuk Res; 2022 Jun; 117():106840. PubMed ID: 35468520
[TBL] [Abstract][Full Text] [Related]
90. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study.
Michot JM; Canioni D; Driss H; Alric L; Cacoub P; Suarez F; Sibon D; Thieblemont C; Dupuis J; Terrier B; Feray C; Tilly H; Pol S; Leblond V; Settegrana C; Rabiega P; Barthe Y; Hendel-Chavez H; Nguyen-Khac F; Merle-Béral H; Berger F; Molina T; Charlotte F; Carrat F; Davi F; Hermine O; Besson C;
Am J Hematol; 2015 Mar; 90(3):197-203. PubMed ID: 25417909
[TBL] [Abstract][Full Text] [Related]
91. MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
Nosrati A; Monabati A; Sadeghipour A; Radmanesh F; Safaei A; Movahedinia S
Ann Hematol; 2019 Jan; 98(1):169-173. PubMed ID: 30306208
[TBL] [Abstract][Full Text] [Related]
92. FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control.
Goatly A; Bacon CM; Nakamura S; Ye H; Kim I; Brown PJ; Ruskoné-Fourmestraux A; Cervera P; Streubel B; Banham AH; Du MQ
Mod Pathol; 2008 Jul; 21(7):902-11. PubMed ID: 18487996
[TBL] [Abstract][Full Text] [Related]
93. [Immunophenotyping and molecular genetic analysis of diffuse large B-cell lymphoma].
Han YS; Xue YQ; Yang HY; Zhang J; Pan JL
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Apr; 30(2):143-7. PubMed ID: 23568722
[TBL] [Abstract][Full Text] [Related]
94. Transformation risk and associated survival outcome of marginal zone lymphoma: A nationwide study.
Sun X; Li H; Yang Y; Wu Y; Kang K; Liu Q; Luo R; Wang L; Zhao A; Niu T
Ann Hematol; 2024 Mar; ():. PubMed ID: 38459154
[TBL] [Abstract][Full Text] [Related]
95. C-MYC overexpression predicts aggressive transformation and a poor outcome in mucosa-associated lymphoid tissue lymphomas.
Huang W; Guo L; Liu H; Zheng B; Ying J; Lv N
Int J Clin Exp Pathol; 2014; 7(9):5634-44. PubMed ID: 25337204
[TBL] [Abstract][Full Text] [Related]
96. Marginal Zone Lymphoma: State-of-the-Art Treatment.
Sindel A; Al-Juhaishi T; Yazbeck V
Curr Treat Options Oncol; 2019 Dec; 20(12):90. PubMed ID: 31807935
[TBL] [Abstract][Full Text] [Related]
97. Primary cutaneous marginal zone B-cell lymphoma: a clinical, histopathological, immunophenotypic and molecular genetic study of 22 cases.
Servitje O; Gallardo F; Estrach T; Pujol RM; Blanco A; Fernández-Sevilla A; Pétriz L; Peyrí J; Romagosa V
Br J Dermatol; 2002 Dec; 147(6):1147-58. PubMed ID: 12452864
[TBL] [Abstract][Full Text] [Related]
98. Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.
Fox LC; Yannakou CK; Ryland G; Lade S; Dickinson M; Campbell BA; Prince HM
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29899297
[TBL] [Abstract][Full Text] [Related]
99. Primary cutaneous B-cell lymphomas: part II. Therapy and future directions.
Suárez AL; Querfeld C; Horwitz S; Pulitzer M; Moskowitz A; Myskowski PL
J Am Acad Dermatol; 2013 Sep; 69(3):343.e1-11; quiz 355-6. PubMed ID: 23957985
[TBL] [Abstract][Full Text] [Related]
100. MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkin lymphoma.
Sanchez-Izquierdo D; Buchonnet G; Siebert R; Gascoyne RD; Climent J; Karran L; Marin M; Blesa D; Horsman D; Rosenwald A; Staudt LM; Albertson DG; Du MQ; Ye H; Marynen P; Garcia-Conde J; Pinkel D; Dyer MJ; Martinez-Climent JA
Blood; 2003 Jun; 101(11):4539-46. PubMed ID: 12560219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]